Pharmaceutical composition for preventing, alleviating, or treating candidiasis, comprising methoxy-apo-enterobactin-based compound as active ingredient

Methoxy-apo-enterobactin compounds derived from Streptomyces ambofaciens CJD34 address the challenge of candidiasis by inhibiting Candida albicans and candidalysin, providing antifungal treatments and reducing infection severity.

WO2026127339A1 Publication Date: 2026-06-18UNIVERSITY INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY +1
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
UNIVERSITY INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
Filing Date
2025-10-21
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Candidiasis, primarily caused by Candida albicans, poses a significant threat to immunocompromised individuals, leading to invasive infections and systemic complications due to biofilm formation and the secretion of candidalysin, with existing treatments lacking effective antifungal agents that inhibit ECE1 gene expression.

⚗Method used

Development of methoxy-apo-enterobactin-based compounds derived from Streptomyces ambofaciens CJD34, which exhibit antifungal activity and inhibit ECE1 gene expression, reducing subcutaneous infection in candidiasis models.

🎯Benefits of technology

The compounds effectively inhibit Candida albicans growth and candidalysin secretion, offering potential treatments for candidiasis through pharmaceutical, cosmetic, and food compositions, reducing fungal cell numbers and abscess size in vivo.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for preventing, alleviating, or treating candidiasis, the composition comprising a methoxy-apo-enterobactin-based compound as an active ingredient, wherein the compound is isolated from a strain of the genus Streptomyces (Streptomyces sp.) and was found to have antifungal activity against Candida albicans and an inhibitory effect on ECE1 gene expression as well as the effect of reducing subcutaneous infection in an in vivo candidiasis model, and thus can be effectively used in related industries.
Need to check novelty before this filing date? Find Prior Art